Diagnosis and treatment options for nerve sheath tumors

Expert Review of Neurotherapeutics

Volumn 5, Issue 4, 2005, Pages 515-523

  Huang, Jason H ^a   Zhang, Jun ^b   Zager, Eric L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Malignant nerve sheath tumors; Nerve sheath tumors; Neurofibromas; Neurofibromatosis; Peripheral nerves; Schwannomas; Schwannomatosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; BRAIN FUNCTION; CANCER SURGERY; CLINICAL FEATURE; DISEASE ASSOCIATION; GENETIC DISORDER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RADIODIAGNOSIS; REVIEW; SCHWANNOMATOSIS; STEREOTAXIC SURGERY; TREATMENT OUTCOME; TUMOR LOCALIZATION;

HUMANS; MAGNETIC RESONANCE IMAGING; MICROSURGERY; NERVE SHEATH NEOPLASMS;

EID: 22544466128     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.4.515     Document Type: Review

References (66)

1. Pilavaki M, Chourmouzi D, Kiziridou A, Skordalaki A, Zarampoukas T, Drevelengas A. Imaging of peripheral nerve sheath tumors with pathologic correlation: pictorial review. Eur. J. Radiol. 52(3), 229-239 (2004).
2. Moukarbel RV, Sabri AN. Current management of head and neck schwannomas. Curr. Opin. Otolaryngol. Head Neck Surg. 13(2), 117-122 (2005).
3. Huang JH, Simon SL, Nagpal S, Nelson PT, Zager EL. Management of patients with schwannomatosis: report of six cases and review of the literature. Surg. Neurol. 62(4), 353-361 (2004).
4. Huang JH, Zaghloul K, Zager EL. Surgical management of brachial plexus region tumors. Surg. Neurol. 61(4), 372-378 (2004).
5. Skovronsky DM, Oberholtzer JC. Pathologic classification of peripheral nerve tumors. Neurosurg. Clin. N. Am. 15(2), 157-166 (2004). Excellent overview of the important pathologic features of different peripheral nerve tumors.
6. Ducatman BS, Scheithauer BW. Postirradiation neurofibrosarcoma. Cancer 51(6), 1028-1033 (1983).
7. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57(10), 2006-2021 (1986). Large clinical series on the treatment and outcome of malignant peripheral nerve sheath tumors.
8. Haraida S, Nerlich AG, Bise K, Wiest I, Schleicher E. Comparison of various basement membrane components in benign and malignant peripheral nerve tumours. Virchows Arch. A. Pathol. Anat. Histopathol. 421(4), 331-338 (1992).
9. Nerlich AG, Haraida S, Wiest I. Basement membrane components as differential markers for mesenchymal tumors of various origin. Anticancer Res. 14(2B), 683-692 (1994).
10. Perrin RG, Guha A. Malignant peripheral nerve sheath tumors. Neurosurg. Clin. N. Am. 15(2), 203-216 (2004). Good overview of the clinical presentation and current management options for malignant peripheral nerve sheath tumors.
11. Stark AM, Buhl R, Hugo HH, Mehdorn HM. Malignant peripheral nerve sheath tumours - eport of 8 cases and review of the literature. Acta Neurochir. (Wien) 143(4), 357-364 (2001).
12. Seymour-Dempsey K, Andrassy RJ. Neurofibromatosis: implications for the general surgeon. J. Am. Coll. Surg. 195(4), 553-563 (2002).
13. Gutmann DH, Aylsworth A, Carey JC et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278(1), 51-57 (1997). Comprehensive review of literature on the management of neurofibromatosis Type 1 and 2 patients.
14. Riccardi VM. Von Recklinghausen neurofibromatosis. N. Engl. J. Med. 305(27), 1617-1627 (1981).
15. Gutmann DH. Recent insights into neurofibromatosis Type 1: clear genetic progress. Arch. Neurol. 55(6), 778-780 (1998).
16. Wallace MR, Marchuk DA, Andersen LB et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249(4965), 181-186 (1990).
17. Parada LF. Neurofibromatosis Type 1. Biochim. Biophys. Acta. 1471(1), M13-M19 (2000).
18. North K. Neurofibromatosis Type 1. Am J Med. Genet. 97(2), 119-127 (2000).
19. Lynch TM, Gutmann DH. Neurofibromatosis 1. Neurol. Clin. 20(3), 841-865 (2002).
20. Trofatter JA, MacCollin MM, Rutter JL et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75(4), 826 (1993).
21. Rouleau GA, Merel P, Lutchman M et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis Type 2. Nature 363(6429), 515-521 (1993). Important early study identifying the gene mutation responsible for neurofibromatosis Type 2.
22. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N. Engl. J. Med. 318(11), 684-688 (1988).
23. Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann. Intern. Med. 113(1), 39-52 (1990).
24. Evans DG, Sainio M, Baser ME. Neurofibromatosis Type 2. J. Med. Genet. 37(12), 897-904 (2000).
25. Jacoby LB, Jones D, Davis K et al. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am. J. Hum. Genet. 61(6), 1293-1302 (1997).
26. MacCollin M, Woodfin W, Kronn D, Short MP. Schwannomatosis: a clinical and pathologic study. Neurology 46(4), 1072-1079 (1996). Important study on the clinical and pathologic features of schwannomatosis.
27. Seppala MT, Sainio MA, Haltia MJ, Kinnunen JJ, Setala KH, Jaaskelainen JE. Multiple schwannomas: schwannomatosis or neurofibromatosis Type 2? J. Neurosurg. 89(1), 36-41 (1998).
28. Purcell SM, Dixon SL. Schwannomatosis. An unusual variant of neurofibromatosis or a distinct clinical entity? Arch. Dermatol. 125(3), 390-393 (1989).
29. Suh JS, Abenoza P, Galloway HR, Everson LI, Griffiths HJ. Peripheral (extracranial) nerve tumors: correlation of MR imaging and histologic findings. Radiology 183(2), 341-346 (1992).
30. Filler AG, Kliot M, Howe FA et al. Application of magnetic resonance neurography in the evaluation of patients with peripheral nerve pathology. J. Neurosurg. 85(2), 299-309 (1996).
31. Maniker AH. Diagnostic steps, imaging, and electrophysiology. Neurosurg. Clin. N. Am. 15(2), 133-144 (2004).
32. Artico M, Cervoni L, Wierzbicki V, D'Andrea V, Nucci F. Benign neural sheath tumours of major nerves: characteristics in 119 surgical cases. Acta Neurochir. (Wien) 139(12), 1108-1116 (1997).
33. Hughes DG, Wilson DJ. Ultrasound appearances of peripheral nerve tumours. Br. J. Radiol. 59(706), 1041-1043 (1986).
34. Martinoli C, Bianchi S, Derchi LE. Ultrasonography of peripheral nerves. Semin. Ultrasound CTMR. 21(3), 205-213 (2000).
35. Huang JH, Samadani U, Zager EL. Brachial plexus region tumors: a review of their history, classification, surgical management, and outcomes. Neurosurgery Quarterly 13(3), 151-161 (2003). Comprehensive review including details about the classification, management and outcome of tumors of the brachial plexus region.
36. Tiel R, Kline D. Peripheral nerve tumors: surgical principles, approaches, and techniques. Neurosurg. Clin. N. Am. 15(2), 167-175 (2004).
37. Abaza MM, Makariou E, Armstrong M, Lalwani AK. Growth rate characteristics of acoustic neuromas associated with neurofibromatosis Type 2. Laryngoscope 106(6), 694-699 (1996).
38. Mendenhall WM, Friedman WA, Amdur RJ, Antonelli PJ. Management of acoustic schwannoma. Am. J. Otolaryngol. 25(1), 38-47 (2004).
39. Deen HG, Ebersold MJ, Harner SG et al. Conservative management of acoustic neuroma: an outcome study. Neurosurgery 39(2), 260-266 (1996).
40. Wiet RJ, Zappia JJ, Hecht CS, O'Connor CA. Conservative management of patients with small acoustic tumors. Laryngoscope 105(8), 795-800 (1995).
41. Darrouzet V, Martel J, Enee V, Bebear JP, Guerin J. Vestibular schwannoma surgery outcomes: our multidisciplinary experience in 400 cases over 17 years. Laryngoscope 114(4), 681-688 (2004).
42. Skrivan J, Zverina E, Betka J, Kluh J, Kraus J. Our surgical experience with large vestibular schwannomas. Otolaryngol. Pol. 58(1), 69-72 (2004).
43. Hasegawa T, Kida Y, Kobayashi T, Yoshimoto M, Mori Y, Yoshida J. Long-term outcomes in patients with vestibular schwannomas treated using gamma knife surgery: 10-year follow-up. J. Neurosurg. 102(1), 10-16 (2005).
44. Kaylie DM, McMenomey SO. Microsurgery vs. gamma knife radiosurgery for the treatment of vestibular schwannomas. Arch. Otolaryngol. Head Neck Surg. 129(8), 903-906 (2003).
45. Litvack ZN, Noren G, Chougule PB, Zheng Z. Preservation of functional hearing after gamma knife surgery for vestibular schwannoma. Neurosurg. Focus 14(5), e3 (2003).
46. Lunsford LD, Niranjan A, Flickinger JC, Maitz A, Kondziolka D. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J. Neurosurg. 102, 195-199 (2005).
47. Kunisada T, Kawai A, Ozaki T, Sugihara S, Taguchi K, Inoue H. A clinical analysis of malignant schwannoma. Acta Med. Okayama 51(2), 87-92 (1997).
48. Wanebo JE, Malik JM, VandenBerg SR, Wanebo HJ, Driesen N, Persing JA. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases. Cancer 71(4), 1247-1253 (1993).
49. Galanis E, Okuno SH, Nascimento AG et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 12(5), 437-445 (2005).
50. Kasper B, Lehnert T, Bernd L et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 34(1), 37-41 (2004).
51. Masui F, Yokoyama R, Soshi S, Beppu Y, Asanuma K, Fujii K. A malignant peripheral nerve-sheath tumour responding to chemotherapy. J. Bone Joint Surg. Br. 86(1), 113-115 (2004).
52. Khanfir K, Alzieu L, Terrier P et al. Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities? Eur. J. Cancer 39(13), 1872-1880 (2003).
53. Pollack A, Zagars GK, Goswitz MS, Pollock RA, Feig BW, Pisters PW. Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Int. J. Radiat. Oncol. Biol. Phys. 42(3), 563-572 (1998).
54. Robinson MH, Keus RB, Shasha D, Harrison LB. Is pre-operative radiotherapy superior to postoperative radiotherapy in the treatment of soft tissue sarcoma? Eur. J. Cancer 34(9), 1309-1316 (1998).
55. Chung WY, Liu KD, Shiau CY et al. Gamma knife surgery for vestibular schwannoma: 10-year experience of 195 cases. J. Neurosurg. 102, 87-96 (2005).
56. Flickinger JC, Kondziolka D, Niranjan A, Lunsford LD. Results of acoustic neuroma radiosurgery: an analysis of 5 years' experience using current methods. J. Neurosurg. 94(1), 1-6 (2001).
57. Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC. Long-term outcomes after radiosurgery for acoustic neuromas. N. Engl. J. Med. 339(20), 1426-1433 (1998). Important clinical study that helps to establish stereotactic radisurgery as the principal alternative to microsurgical resection of vestibular schwannomas.
58. Jhanwar SC, Chen Q, Li FP, Brennan MF, Woodruff JM. Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST). Cancer Genet. Cytogenet. 78(2), 138-144 (1994).
59. Kourea HP, Cordon-Cardo C, Dudas M, Leung D, Woodruff JM. Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am. J. Pathol. 155(6), 1885-1891 (1999).
60. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am. J. Pathol. 155(6), 1879-1884 (1999).
61. Angelov L, Salhia B, Roncari L, McMahon G, Guha A. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res. 59(21), 5536-5541 (1999).
62. Perosio PM, Brooks JJ. Expression of growth factors and growth factor receptors in soft tissue tumors. Implications for the autocrine hypothesis. Lab. Invest. 60(2), 245-253 (1989).
63. Hirota S, Nomura S, Asada H, Ito A, Morii E, Kitamura Y. Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch. Pathol. Lab. Med. 117(10), 996-999 (1993).
64. Arbiser JL, Flynn E, Barnhill RL. Analysis ofvascularity of human neurofibromas. J. Am. Acad. Dermatol. 38(6), 950-954 (1998).
65. DeClue JE, Heffelfinger S, Benvenuto G et al. Epidermal growth factor receptor expression in neurofibromatosis Type 1-related tumors and NF1 animal models. J. Clin. Invest. 105(9), 1233-1241 (2000).
66. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch. Neurol. 45(5), 575-578 (1988).